Andrzej Jakubowiak to Prospective Studies
This is a "connection" page, showing publications Andrzej Jakubowiak has written about Prospective Studies.
Connection Strength
0.122
-
Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. Blood. 2011 Jul 21; 118(3):535-43.
Score: 0.054
-
Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice. Haematologica. 2023 08 01; 108(8):2192-2204.
Score: 0.032
-
Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis. Blood Cancer J. 2020 08 07; 10(8):80.
Score: 0.026
-
Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia. Blood. 2008 Sep 01; 112(5):1993-2003.
Score: 0.011